Disclosed is a pharmaceutical combination comprising a cytotoxic antineoplastic agent selected from the group consisting of paclitaxel, docetaxel, doxorubicin, and gemcitabine or a pharmaceutically acceptable salt thereof and a CDK inhibitor or an enantiomer or a pharmaceutically acceptable salt or solvate thereof, wherein said CDK inhibitor is represented by formula I, wherein the substituents are as described within the specification. Further disclosed is the use of a CDK inhibitor of formula I in combination with a cytotoxic antineoplastic agent selected from the group consisting of paclitaxel, docetaxel, doxorubicin, and gemcitabine or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of cancer selected from the group consisting of breast cancer, small cell lung cancer, non small-cell lung cancer, ovarian cancer, pancreatic cancer, gastric cancer, colorectal cancer and hepatocellular carcinoma.
